CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cardurion Pharmaceuticals, a biotechnology company focused on the development of novel, next-generation therapeutics for the treatment of cardiovascular diseases, today announced the appointment of industry leader, Jeb Keiper, as an independent member of its Board of Directors. Mr. Keiper joins founder Michael Mendelsohn, M.D., Ken Novack, Ed Mascioli, M.D. and chief executive officer Daniel Bloomfield, M.D. as members, along with board observers, Stephen Hitchcock, Ph.D. and Keith Gottesdiener, M.D.
“We are fortunate to have amassed a tremendous breadth and depth of expertise in drug discovery, development, and business amongst our board members, observers and advisors, which positions Cardurion well to deliver on our vision of becoming the world’s leading cardiovascular drug company,” said Daniel Bloomfield, M.D., chief executive officer at Cardurion Pharmaceuticals. “We are thrilled to have Jeb share his expertise and leadership skills as Cardurion takes on the challenges and opportunities of the company’s next critical phase of growth.”
Jeb Keiper has 20 years of experience in the pharmaceutical and biotech industries with extensive expertise in financing and business development transactions. Mr. Keiper currently serves as chief financial officer and chief business officer at Nimbus Therapeutics, LLC, where he has overseen over $700m of capital inflows via a variety of financing and partnering transactions since joining in 2014. Prior to joining Nimbus, Mr. Keiper was vice president of business development at GSK Oncology and spent a decade at GSK in various business development leadership roles. Mr. Keiper led the oncology portion of the GSK-Novartis 3-business swap for $16b announced in April 2014. Earlier in his career, Mr. Keiper was a consultant at McKinsey and Company and worked in business development at TransForm Pharmaceuticals. Mr. Keiper began his career at Pfizer R&D as a bench chemist. He received four degrees from MIT: one in Chemistry, two in Chemical Engineering, and an MBA from MIT Sloan.
“Cardurion has built an exceptional company focused on addressing multiple pathways in the cardiomyocyte,” said Mr. Keiper. “I look forward to working with the leadership team and fellow board members as Cardurion continues to build a novel portfolio of clinical and preclinical programs for patients with cardiovascular disease.”
For additional information on Cardurion Pharmaceuticals’ board and leadership team, please visit the company’s website: http://www.cardurion.com.
About Cardurion Pharmaceuticals
Cardurion is a biotechnology
company with both clinical and preclinical programs focused on the
development of novel, next-generation therapeutics for the treatment of
heart failure and other cardiovascular diseases. Led by two
physician-scientists with extensive experience in cardiovascular
science, medicine and drug development, Cardurion’s unique programs and
strongly collaborative environment enable the company to deliver
promising treatments that target major unmet needs. Cardurion has
facilities in Cambridge, Massachusetts and Shonan, Japan. For more
information, please visit the company’s website at http://www.cardurion.com.
Cardurion Pharmaceuticals’ Forward Looking Statements
This
press release contains forward-looking statements, all of which are
qualified in their entirety by this cautionary statement. Any statements
contained herein that do not describe historical facts, are
forward-looking statements that are based on management’s expectations
and are subject to certain factors, risks and uncertainties that may
cause actual results, outcomes, timing and performance to differ
materially from those expressed or implied by such statements. These
factors, risks and uncertainties include, but are not limited to: the
costs and uncertainties associated with our research efforts and other
discovery activities; the inherent uncertainties associated with the
conduct, timing and results of preclinical and clinical studies of our
product candidates; and the adequacy of our capital resources and
availability of additional funding. Except as otherwise noted, these
forward-looking statements speak only as of the date of this press
release, and we undertake no obligation to update or revise any of such
statements to reflect events or circumstances occurring after this press
release. We caution readers not to place undue reliance on the
forward-looking statements contained in this press release.
The safety and efficacy of the agent discussed herein are under investigation and have not been established. There is no guarantee that the agent will receive regulatory approval and become commercially available for the uses being investigated. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.
